Detecting ultra-rare analytes for  infectious disease and beyond

MEET ACCELEVIRDX

WHO WE ARE

Accelevir Diagnostics is a Maryland biotechnology company developing innovative assays for ultra-rare analytes in infectious disease and beyond. Our team brings expertise in virology, immunology, and assay commercialization.

OUR APPROACH

We employ advanced ddPCR, qPCR, and sequencing as well as culture-based approaches to develop scalable assays for difficult to detect pathogens that can support the continuum from basic research through clinical trials. We are currently focused on advancing new assays for persistent HIV-1 and other clinically important viral infections.

COLLABORATIONS AND FUNDING

To date, we have received over $12M in federal, state and private funding to advance our assays. We are actively working with leading academic and bio-pharma groups to provide our assays in support of translational research and early-stage clinical trials.

 
 

RECENT NEWS

AND PUBLICATIONS

December 2021

Congratulations to the AccelevirDx team for participating as authors in six outstanding peer-reviewed publications this year

NIH

August

2021

AccelevirDx announces receipt of NIH SBIR Phase I funding to support expansion of ddPCR test for HIV persistence to additional clades

NIH

July 2021

AccelevirDx announces receipt of NIH SBIR Phase I funding to develop a novel sequencing based assay for in-depth assessment of HIV-1 bNAb susceptibility and resistance

January 2021

AccelevirDx announces receipt of CLIA registration and State of Maryland laboratory license

December 2020

Congratulations to the AccelevirDx team for participating as authors in five outstanding peer-reviewed publications this year

October

2020

AccelevirDx is proud to announce issuance of a US patent describing our innovative methods for quantitative characterization of persistent HIV proviruses

NIH

May 2020

AccelevirDx announces award of an NIH contract to expand subtype coverage of test for HIV persistence

NIH

April 2020

AccelevirDx announces award of a multi-year NIH Cooperative Agreement to establish a centralized testing resource for HIV persistence

March 2020

AccelevirDx is proud to announce our participation in six accepted abstracts at CROI 2020

February 2020

AccelevirDx announces joint publication with Deeks lab at UCSF describing differential dynamics of intact and defective HIV-1 proviruses in people on ART (JCI Insight, 2020, PMID 32045386)

NIH

January 2019

AccelevirDx announces receipt of NIH SBIR Phase I funding to support SIV/SHIV ddPCR assay development

!

December 2019

AccelevirDx is excited to announce our move to expanded laboratories at Columbus Center! We are thrilled to join a wonderful group of exciting biotech companies in Baltimore's Inner Harbor.

NSF

September 2019

AccelevirDx announces receipt of NSF Phase IIB funding to support expanded ddPCR assay development and sequencing

February 2019

AccelevirDx announces joint publication with Siliciano lab at Johns Hopkins describing novel HIV assay (Nature, 2019, PMID 30700913)

GET IN TOUCH

701 E. Pratt St.
Baltimore, MD 21202